Drug Type CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD22 inhibitors(CD22 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Malignant Neoplasm | Phase 2 | China | 20 Aug 2017 | |
| CD19 Expressing Malignancies | Phase 2 | China | 20 Aug 2017 | |
| CD22 positive lymphoma | Phase 2 | China | 20 Aug 2017 | |
| Chronic Lymphocytic Leukemia | Phase 2 | China | 20 Aug 2017 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 2 | China | 20 Aug 2017 |





